LANARKSHIRE AREA DRUG & THERAPEUTICS COMMITTEE

Minute of the Meeting
Wednesday 21st November 2018 @ 10.00am
Boardroom, Kirklands Hospital

Present:
Dr Mehrdad Malekian
Mr George Lindsay
Miss Katrina Mackie
Dr Vijay Sonthalia
Mrs Christine Gilmour
Mrs Karen Patterson
Mrs Anne Milne
Mrs Linda Johnstone
Mrs Gail Richardson
Mrs Mary Gilfillan
Mr John Milne
Miss Emma Harris

In attendance Jennifer Bernardo

<table>
<thead>
<tr>
<th>2018/175 1</th>
<th>Apologies for Absence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stephanie Dundas, Tasmin Sommerfield, Dr Mhairi Simpson, Ann Auld and Bill Angus.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2018/176 2</th>
<th>Declaration of Interest</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No one had any declaration of interest for the items discussed today.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2018/177 3</th>
<th>Matters arising not covered elsewhere on the agenda</th>
</tr>
</thead>
<tbody>
<tr>
<td>a.</td>
<td>Ratification of minutes of meeting 24th October 2018</td>
</tr>
<tr>
<td></td>
<td>The minute of the 24th October meeting was agreed and can now be published.</td>
</tr>
<tr>
<td>b.</td>
<td>Medicine Shortages</td>
</tr>
<tr>
<td></td>
<td>There was a useful discussion during which Mrs Gilmour indicated a plan to share intelligence about shortages with a wider group of specialist pharmacists so that potential problems can be identified at an early stage. Consideration was given to wider distribution of raw data with GPs and hospital doctors but the conclusion was that this was not the best way forward.</td>
</tr>
</tbody>
</table>
c. Adrenaline – Epipen

Mr Lindsay spoke to the attachments distributed with the agenda which indicated that the pressures were lessening but diligence with the updated national supply protocol was still required.

d. LAIA

Miss Mackie spoke to the updated document which was ratified by the committee and can now be implemented.

2018/178 4 SMC NEW Submissions  - confidential until Monday 10th December 2018.

FULL SUBMISSIONS

Nivolumab (Opdivo®) (SMC2112)
This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).

Ciclosporin (Verkazia®) (SMC2111)
This was noted and will be referred to specialists in Ophthalmology.

RESUBMISSION

Pertuzumab (Perjeta®) (SMC2119 - previous SMC No.1121/16)
This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).

Ocrelizumab (Ocrevus®) (SMC2121 - previous SMC No.1344/18)
This was noted and will be referred to specialists in Neurology.

ABBREVIATED SUBMISSION

Brivaracetam (Briviact®) (SMC2113)
This was noted and will be referred to specialists in Paediatrics.

NON SUBMISSION

Pembrolizumab (Keytruda®) (SMC2143)
This was noted.

FOR INFORMATION

Evolocumab (Repatha®) 1148/16: SMC published advice for evolocumab (Repatha®) in February 2017 and accepted for restricted use within NHS Scotland. Please note the ‘For specialist use only’ restriction was not intended to restrict use to specialist prescribing only. Initiation in secondary care with prescribing transferred to primary care thereafter is in line with SMC advice.
**Tocilizumab (RoActemra®):** tocilizumab (RoActemra®) has been granted a marketing authorisation for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older. Tocilizumab must be made available prior to infusion of CAR T cell therapy therefore the costs should be captured as part of the economic case put forward within CAR T cell therapy submissions. SMC will not assess tocilizumab for use in this indication separately.

**Ocriplasmin (Jetrea®) (892/13):** ocriplasmin (Jetrea®) is now only available as a 0.375mg/0.3mL ‘ready-diluted’ formulation, which is manufactured by Oxurion NV, formerly known as ThromboGenics NV. The new formulation is out of SMC remit since there is no associated change to the licensed indication and it costs the same as the previous formulation (0.5mg/0.2mL concentrate for solution for injection) which it replaces. SMC advice for ocriplasmin (Jetrea®) (892/13) remains valid.

2018/179  5  **SMC follow up**

Miss Mackie talked the committee through the SMC follow-up which had been previously circulated. A flowchart outlining the ADTC process for SMC advice was discussed and will come back to the next meeting, following some minor amendments. Where necessary updates to previous ADTC bulletins will also be made by Miss Mackie.

2018/180  6  **Lanarkshire Formulary**

Miss Mackie discussed amendments to both the respiratory and Primary Care Wound Management Formulary. Acetylcysteine (NACSYS®) is now the preferred choice mucolytic. Due to Scottish Drug Tariff changes Polymem Adhesive 10cmx13cm, Kaltostat 10cmx10cm and 15cmx15cm will be removed. Two replacement products for Kaltostat will be added – 10cmx20cm and 15cmx25cm. There is no replacement for Polymem Adhesive. The Primary Care Simple Dressings / Tapes / Sundries / Bandages formulary was also presented. All items were ratified by the committee.

2018/181  7  **Clinical Protocols**

(a)  **Dupilumab**

This protocol was ratified by the ADTC.

(b)  **Dermatology biologics pathway**

There was useful discussion about the draft protocol. A number of issues were identified such as

- clarity of cost effective choice taking all factors including administration locations and supply routes into consideration
- consistency between information in the tables within the document
- consistency with SMC recommendations and restrictions
- clarity of decision making criteria when several agents are grouped together.

**ALL:**

**MM:**
All members are asked to give any further feedback to Dr Malekian who will facilitate supportive feedback to Dermatology with the offer of joint working with Jono Cavan, Head of Pharmacy at UHM with a view to a modified draft coming back to the ADTC for ratification in December or January.

<table>
<thead>
<tr>
<th>2018/182 8</th>
<th>ADTC Bulletin</th>
</tr>
</thead>
<tbody>
<tr>
<td>This was noted.</td>
<td><strong>KM</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2018/183 9</th>
<th>Unlicensed Medicines</th>
</tr>
</thead>
<tbody>
<tr>
<td>There was nil to note at this meeting.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2018/184 10</th>
<th>NICE/HIS Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>There was nil to note at this meeting.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2018/185 11</th>
<th>Medication and Clinical risk in Lanarkshire</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://www.gov.uk/drug-safety-update">https://www.gov.uk/drug-safety-update</a></td>
<td><strong>EH</strong></td>
</tr>
</tbody>
</table>

There was useful discussion which highlighted the recent safety update relating to Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use. It was agreed that reiteration of the advice within the NHS Lanarkshire Prescribing Notes publication was the appropriate action.

<table>
<thead>
<tr>
<th>2018/186 12</th>
<th>Regional Cancer Advisory Network</th>
</tr>
</thead>
<tbody>
<tr>
<td>There was nil to note at this meeting.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2018/187 13</th>
<th>Patient Safety Alerts</th>
</tr>
</thead>
<tbody>
<tr>
<td>There was nil to note at this meeting.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2018/188 14</th>
<th>Lay member related items</th>
</tr>
</thead>
<tbody>
<tr>
<td>There was nil to note at this meeting.</td>
<td></td>
</tr>
</tbody>
</table>
| 2018/189 15 | **Correspondence**  
  a. **ADTC Collaborative**  
    (i) **Correspondance**  
    SPSP Webex  
    This was noted.  
    (ii) **October Newsletter**  
    This was noted.  
    (iii) **Biosimilir Update Report**  
    This was noted.  
    (iv) **Medicine in Scotland**  
    This was noted  
    (v) **Valproate Safety**  
    Mr Lindsay will liaise with Dr McLellan in order to provide the ADTC with an update at the December meeting. | GL |
| 2018/190 16 | **AOCB**  
  (i) **NHS Scotland Formulary for Pre-labelled Medicines for Unscheduled Care (Third Edition)**  
    This was noted.  
  (ii) **Cannabis Prescribing**  
    There was a useful discussion around the draft NHS Lanarkshire document and Mrs Gilmour indicated that she would welcome comments by Friday 23rd November with a view to finalising the document shortly thereafter. | All |
| 2018/191 17 | **Date of next meeting**  
  Wednesday 19th December 2018 @ 10am Boardroom, Kirklands |